These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20836674)

  • 1. Chronic lymphocytic leukemia: planning for an aging population.
    Gribben JG
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1389-94. PubMed ID: 20836674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How I treat CLL up front.
    Gribben JG
    Blood; 2010 Jan; 115(2):187-97. PubMed ID: 19850738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.
    Vojdeman FJ; Van't Veer MB; Tjønnfjord GE; Itälä-Remes M; Kimby E; Polliack A; Wu KL; Doorduijn JK; Alemayehu WG; Wittebol S; Kozak T; Walewski J; Abrahamse-Testroote MC; van Oers MH; Geisler CH
    Leuk Lymphoma; 2017 Mar; 58(3):594-600. PubMed ID: 27484290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of elderly and unfit patients with chronic lymphocytic leukemia.
    Mauro FR; Salaroli A; Caputo MD; Colafigli G; Petrucci L; Campanelli M; Ferretti A; Guarini AR; Foà R
    Expert Rev Hematol; 2016 Dec; 9(12):1165-1175. PubMed ID: 27796157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update in the management of chronic lymphocytic leukemia.
    Maddocks KJ; Lin TS
    J Hematol Oncol; 2009 Jul; 2():29. PubMed ID: 19619273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia.
    Rai KR
    J Hematol Oncol; 2015 Jul; 8():85. PubMed ID: 26170206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
    Lee LJ; Toze CL; Huang SJT; Gillan TL; Connors JM; Sehn LH; Bruyere H; Leitch H; Ramadan KM; Gerrie AS
    Leuk Lymphoma; 2018 Jun; 59(6):1356-1363. PubMed ID: 29032719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.
    Steingrímsson V; Lund SH; Dickman PW; Weibull CE; Björkholm M; Landgren O; Kristinsson SY
    Eur J Haematol; 2022 Feb; 108(2):145-153. PubMed ID: 34714556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death.
    Rotbain EC; Niemann CU; Rostgaard K; da Cunha-Bang C; Hjalgrim H; Frederiksen H
    Leukemia; 2021 Sep; 35(9):2570-2580. PubMed ID: 33603143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
    Al-Sawaf O; Bahlo J; Robrecht S; Fischer K; Herling CD; Hoechstetter M; Fink AM; von Tresckow J; Langerbeins P; Cramer P; Stilgenbauer S; Wendtner CM; Eichhorst B; Hallek M; Goede V
    Br J Haematol; 2018 Dec; 183(5):727-735. PubMed ID: 30460980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.
    Huang SJ; Chan J; Bruyère H; Allan LL; Gerrie AS; Toze CL
    Leuk Res; 2019 Sep; 84():106193. PubMed ID: 31325731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
    Iovino L; Shadman M
    Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist.
    Pinilla-Ibarz J; Emole J
    Cancer Control; 2015 Oct; 22(4 Suppl):7-16. PubMed ID: 26618341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
    Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K; Flick ED; Kiselev P; Sharman JP
    BMC Cancer; 2017 Mar; 17(1):198. PubMed ID: 28302090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Lymphocytic Leukemia in the Elderly: Epidemiology and Proposed Patient-Related Approach.
    Balducci L; Dolan D
    Cancer Control; 2015 Oct; 22(4 Suppl):3-6. PubMed ID: 26618340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic lymphocytic leukemia in Iceland from 2003 to 2013: Incidence, presentation and diagnosis].
    Olafsson GB; Steingrimsdottir H; Vidarsson B; Halldorsdottir AM
    Laeknabladid; 2016 Apr; 102(4):171-7. PubMed ID: 27197124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S132-8. PubMed ID: 22226097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.